Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights
Provided By GlobeNewswire
Last update: Aug 19, 2025
Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301
Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026
3.94
-0.24 (-5.74%)
NASDAQ:CINGW (8/28/2025, 4:00:05 PM)
0.05
0 (0%)
Find more stocks in the Stock Screener
